Please login to the form below

bictegravir

This page shows the latest bictegravir news and features for those working in and with pharma, biotech and healthcare.

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) product.

ViiV builds case for switching to its two-drug HIV combinations

ViiV needs to convince patients, prescribers and payers that there is a real benefit to that approach if it is to challenge drugs like Gilead’s three-drug Biktarvy
ViiV bags EU okay for new two-drug HIV therapy

bictegravir/emtricitabine/tenofovir alafenamide) product.
Shingrix lifts GSK in Q1, but two more vaccines are culled

such as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) has started to chip away at growth levels.
Dovato approval key for Glaxo in HIV treatment

This gives the company the upperhand over its chief rival, Gilead, which has come to dominate this segment since it launched Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide [TAF]) in February 2018.
GSK’s says depot HIV injection works over three years

drug tablet Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

More from news
Approximately 2 fully matching, plus 19 partially matching documents found.

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

Add my company

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

4 ways to recruit Alzheimer’s disease patients for your clinical trial: What key things do you need to remember to reach patients living with Alzheimer’s disease?...
Integrating competitive intelligence into business development, licensing and M&A strategy: The advantages of partnering with a competitive intelligence or knowledge management team...
Reaching patients and HCPs during the pandemic: COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...